On Wednesday, Mobile TeleSystems OJSC (ADR) (NYSE:MBT)’s shares inclined 3.47% to $9.84.
Mobile TeleSystems OJSC (ADR) (MBT) a global consulting, technology services and outsourcing company, declared that it was named to the “25 Most Promising Cloud Services Vendors 2015″ in the latest issue of Outsourcing Gazette, a print magazine which provides a platform to thinkers, practitioners, strategists and visionaries in the outsourcing community. Among the leading service providers dominating the landscape in the cloud space recently, Bell Integrator stood out as the “Company of the Month.”
By presenting the “25 Most Promising Cloud Services Vendors,” Outsourcing Gazette’s aim is to educate its audience about best of breed service providers for their needs and to assist CIOs select the right service provider from literally hundreds of vendors providing almost similar services.
A distinguished panel of CEOs, CIOs, Analysts and Industry Experts together with the Outsourcing Gazette editorial team selected Bell Integrator to the list noting the company’s service offering, core competencies, client testimonials and other industry recognitions.
Most recently Bell Integrator was honored with the IBM’s Best Partner Award in the IBM Cloud for Telecom category. These recognitions highlight Bell Integrator’s expertise and achievements in the cloud computing market.
Mobile TeleSystems OJSC provides telecommunication services in Russia and the Commonwealth of Independent States. The company offers a range of mobile and fixed line voice and data telecommunications services, counting data transfer, broadband, pay-TV, and various value-added services, in addition to sells equipment and accessories.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s shares gained 6.88% to $2.02.
AVEO Pharmaceuticals, Inc. (AVEO) declared that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors.
AVEO recently presented results from the BATON-CRC study, a 265 patient randomized trial exploring the combination of mFOLFOX6 and tivozanib or bevacizumab as first-line treatment in patients with advanced metastatic CRC, at the 2015 American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference. Among the predefined biomarkers explored in this study, neuropilin-1 (NRP-1), a signaling protein known to bind to VEGF-A in serum, was found to be a potential prognostic marker for angiogenesis inhibitor activity and may be predictive of tivozanib activity relative to bevacizumab.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
At the end of Wednesday’s trade, Tyson Foods, Inc. (NYSE:TSN)‘s shares surged 0.76% to $42.23.
Mexico’s Federal Economic Competition Commission has approved the sale of Tyson Foods, Inc.’s (TSN) poultry business in Mexico to Pilgrim’s Pride, which is part of a wholly-owned partner of JBS SA (BM&FBovespa — Novo Mercado:JBSS3) (JBSAY).
The commission, which has been reviewing the transaction, recently voted to permit the deal to proceed.
After the sale is accomplished, Tyson Foods will continue to serve customers in Mexico. The company will supply them with U.S.-produced chicken in addition to chicken produced in Mexico, in part through a co-packaging arrangement with Pilgrim’s Pride.
Tyson Foods, Inc., together with its auxiliaries, produces, distributes, and markets chicken, beef, pork, prepared foods, and related allied products worldwide. The company breeds and raises chickens; and processes live chickens into fresh, frozen, and value-added chicken products.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), ended its Wednesday’s trading session with -0.43% loss, and closed at $60.14.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) declared positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD) designed to evaluate the efficacy of SD-809 (deutetrabenazine) in the treatment of moderate to severe tardive dyskinesia. Top-line data showed that the study met its primary endpoint and demonstrated a positive trend in all secondary endpoints. Importantly, the study also showed a favorable safety and tolerability profile, counting low rates of depression, somnolence, insomnia and akathisia.
The primary endpoint of ARM-TD was the change in the Abnormal Involuntary Movement Scale (AIMS) from baseline to end of therapy, assessed by blinded centralized video rating. The study results show patients taking SD-809 achieved an improvement of 3.0 points on the AIMS score from baseline to end of therapy contrast to 1.6 points in placebo (p = 0.0188) for a clinically meaningful effect. Study results also demonstrated a favorable safety and tolerability profile of SD-809. Fewer patients taking SD-809 than placebo practiced serious adverse events (SAEs) Three patients suspended from the study for adverse events (1 in SD-809 group vs. 2 in placebo group). For all other side effects stated in the study, rates in the SD-809 group were similar or lower than the placebo group. Further analysis of the additional data from the study is ongoing and details will be shared at future medical meetings and through peer-reviewed publication.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
